organization · Reporting owner
Aperture Ventures IV Management, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Trevi Therapeutics, Inc.
Report date May 09, 2019 · Filed May 13, 2019
Jointly reported with Aperture Venture Partners IV, L.P.
Section 16 reporting ended · disclosed 2019-05-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 344,963 |
Last balance in matching sequence
After 2019-05-09 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2019-05-09 · Conversion · Acquired 232,963 · Balance 232,963 F1: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: Aperture Ventures IV Management, LLC, the general partner of Aperture Venture Partners IV, L.P., has sole voting and investment control with respect to shares of the Issuer's common stock held by Aperture Venture Partners IV, L.P. Row 2 · 2019-05-09 · Purchase · Acquired 112,000 · Balance 344,963 F2: Aperture Ventures IV Management, LLC, the general partner of Aperture Venture Partners IV, L.P., has sole voting and investment control with respect to shares of the Issuer's common stock held by Aperture Venture Partners IV, L.P. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-05-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-05-09 · Conversion · Disposed 2,054,795 · Balance 0 F1: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: Aperture Ventures IV Management, LLC, the general partner of Aperture Venture Partners IV, L.P., has sole voting and investment control with respect to shares of the Issuer's common stock held by Aperture Venture Partners IV, L.P. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2: Aperture Ventures IV Management, LLC, the general partner of Aperture Venture Partners IV, L.P., has sole voting and investment control with respect to shares of the Issuer's common stock held by Aperture Venture Partners IV, L.P.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2019 Filed May 13, 2019 17:01 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | ConversionSeries C Preferred Stock · Derivative | 2,054,795 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-013254 · doc4.xml · derivative · entry 3 Aperture Venture Partners IV, L.P. · CIK 0001659119 · 10% owner Aperture Ventures IV Management, LLC · CIK 0001775271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 232,963 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.direct: Aperture Ventures IV Management, LLC, the general partner of Aperture Venture Partners IV, L.P., has sole voting and investment control with respect to shares of the Issuer's common stock held by Aperture Venture Partners IV, L.P. Read SEC document |
| May 09, 2019 Filed May 13, 2019 17:01 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | PurchaseCommon Stock | 112,000 | $10.00 | $1,120,000.00 |
DisclosureSEC source: 0000899243-19-013254 · doc4.xml · nonDerivative · entry 2 Aperture Venture Partners IV, L.P. · CIK 0001659119 · 10% owner Aperture Ventures IV Management, LLC · CIK 0001775271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,963 F2 · ownership.direct: Aperture Ventures IV Management, LLC, the general partner of Aperture Venture Partners IV, L.P., has sole voting and investment control with respect to shares of the Issuer's common stock held by Aperture Venture Partners IV, L.P. Read SEC document |
| May 09, 2019 Filed May 13, 2019 17:01 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | ConversionCommon Stock | 232,963 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-013254 · doc4.xml · nonDerivative · entry 1 Aperture Venture Partners IV, L.P. · CIK 0001659119 · 10% owner Aperture Ventures IV Management, LLC · CIK 0001775271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.direct: Aperture Ventures IV Management, LLC, the general partner of Aperture Venture Partners IV, L.P., has sole voting and investment control with respect to shares of the Issuer's common stock held by Aperture Venture Partners IV, L.P. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.